$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio

$pbio Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223012010 Filed on April 12, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$740.6K	$607.2K	$1.729M
YoY Change	54.29%	92.63%	-13.64%
Cost Of Revenue	$358.6K	$1.271M	$2.014M
YoY Change	14.08%	642.23%	113.71%
Gross Profit	$382.0K	-$664.1K	-$284.7K
YoY Change	130.6%	-561.46%	-126.86%
Gross Profit Margin	51.58%	-109.38%	-16.46%
Selling, General & Admin	$3.584M	$630.0K	$3.644M
YoY Change	269.36%	-42.86%	-12.06%
% of Gross Profit	938.31%
Research & Development	$435.6K	$252.9K	$969.5K
YoY Change	54.71%	-3.65%	-11.98%
% of Gross Profit	114.05%
Depreciation & Amortization	$28.11K	$51.80K	$33.25K
YoY Change	-19.91%	94.74%	-69.81%
% of Gross Profit	7.36%
Operating Expenses	$4.020M	$882.9K	$4.614M
YoY Change	221.08%	-35.32%	-12.04%
Operating Profit	-$3.638M	-$1.547M	-$4.898M
YoY Change	234.87%	26.68%	17.04%
Interest Expense	$3.894M	-$3.978M	$10.44M
YoY Change	-252.1%	33.56%	-170.02%
% of Operating Profit
Other Income/Expense, Net	-$3.220M	$8.750K	-$11.18M
YoY Change	91640.43%	-107.34%	-30.0%
Pretax Income	-$6.858M	-$4.458M	-$16.08M
YoY Change	61.75%	14.92%	-20.23%
Income Tax
% Of Pretax Income
Net Earnings	-$6.858M	-$4.890M	-$16.08M
YoY Change	61.75%	26.05%	-20.23%
Net Earnings / Revenue	-925.98%	-805.4%	-929.64%
Basic Earnings Per Share	-$0.46		-$1.61
Diluted Earnings Per Share	-$0.46	-$0.38	-$1.61
COMMON SHARES
Basic Shares Outstanding	15.87M shares	11.07M shares	11.06M shares
Diluted Shares Outstanding	15.84M shares		11.06M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$239.0K	$3.870K	$3.870K
YoY Change	101.2%	-97.08%	-97.08%
Cash & Equivalents	$239.0K	$3.865K	$3.870K
Short-Term Investments
Other Short-Term Assets	$257.6K	$257.5K	$257.5K
YoY Change	39.26%	-39.06%	-39.06%
Inventory	$666.0K	$686.4K	$686.4K
Prepaid Expenses
Receivables	$392.2K	$295.4K	$295.4K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.555M	$1.243M	$1.243M
YoY Change	-20.52%	-33.06%	-33.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$99.87K	$103.4K	$385.5K
YoY Change	-78.86%	-10.79%	-24.63%
Goodwill
YoY Change
Intangibles	$295.7K	$317.3K
YoY Change		-21.43%
Long-Term Investments	$71.70K	$63.64K	$63.64K
YoY Change	-9.37%	6.11%	6.1%
Other Assets
YoY Change
Total Long-Term Assets	$659.1K	$766.4K	$766.4K
YoY Change	-29.43%	-21.41%	-21.41%
TOTAL ASSETS
Total Short-Term Assets	$1.555M	$1.243M	$1.243M
Total Long-Term Assets	$659.1K	$766.4K	$766.4K
Total Assets	$2.214M	$2.010M	$2.010M
YoY Change	-23.4%	-29.05%	-29.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$769.0K	$637.2K	$637.2K
YoY Change	15.59%	20.71%	20.71%
Accrued Expenses	$2.788M	$2.807M	$2.807M
YoY Change	14.27%	27.23%	27.23%
Deferred Revenue
YoY Change
Short-Term Debt	$19.56M	$20.10M	$20.10M
YoY Change	23.81%	42.57%	42.57%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$34.40M	$34.40M	$34.40M
YoY Change	26.23%	39.71%	39.71%
LONG-TERM LIABILITIES
Long-Term Debt	$163.8K	$150.0K	$150.0K
YoY Change	9.23%	0.0%	0.0%
Other Long-Term Liabilities	$97.20K	$141.8K	$141.8K
YoY Change	-58.78%	-46.74%	-46.74%
Total Long-Term Liabilities	$261.0K	$291.8K	$291.8K
YoY Change	-32.34%	-29.89%	-29.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.40M	$34.40M	$34.40M
Total Long-Term Liabilities	$261.0K	$291.8K	$291.8K
Total Liabilities	$34.66M	$34.70M	$34.70M
YoY Change	25.42%	38.55%	38.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$141.1M	-$133.8M
YoY Change		13.15%
Common Stock	$180.6K	$136.8K
YoY Change		50.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$32.45M	-$32.69M	-$32.69M
YoY Change
Total Liabilities & Shareholders Equity	$2.214M	$2.010M	$2.010M
YoY Change	-23.4%	-29.05%	-29.05%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$6.858M	-$4.890M	-$16.08M
YoY Change	61.75%	26.05%	-20.23%
Depreciation, Depletion And Amortization	$28.11K	$51.80K	$33.25K
YoY Change	-19.91%	94.74%	-69.81%
Cash From Operating Activities	-$422.2K	-$1.427M	-$4.478M
YoY Change	-44.17%	81.83%	-8.02%
INVESTING ACTIVITIES
Capital Expenditures	$3.000K	$10.00	$20.76K
YoY Change	-363.16%	-100.01%	-116.88%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$3.000K	-$10.00	-$20.76K
YoY Change	163.16%	-99.99%	-83.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$25.00K
YoY Change			-97.57%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$660.4K	1.200M	$4.370M
YoY Change	-11.23%	222.72%	-14.4%
NET CHANGE
Cash From Operating Activities	-$422.2K	-1.427M	-$4.478M
Cash From Investing Activities	-$3.000K	-10.00	-$20.76K
Cash From Financing Activities	$660.4K	1.200M	$4.370M
Net Change In Cash	$235.2K	-227.0K	-$128.4K
YoY Change	-1840.62%	-57.27%	-212.9%
FREE CASH FLOW
Cash From Operating Activities	-$422.2K	-$1.427M	-$4.478M
Capital Expenditures	$3.000K	$10.00	$20.76K
Free Cash Flow	-$425.2K	-$1.427M	-$4.499M
YoY Change	-43.69%	114.16%	-5.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6636523	shares
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000830656
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022	PBIO	Deemed Dividends On Beneficial Conversion Feature DeemedDividendsOnBeneficialConversionFeature		usd
CY2021	PBIO	Stock Issued During Period Value Stock Issuance Of Common Stock For Non Cash Warrant Exercise StockIssuedDuringPeriodValueStockIssuanceOfCommonStockForNonCashWarrantExercise		usd
CY2022	PBIO	Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock		usd
CY2021	PBIO	Allowance For Inventory Reserve AllowanceForInventoryReserve		usd
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	PBIO	Common Stock Issued For Noncash Warrant Exercise CommonStockIssuedForNoncashWarrantExercise		usd
CY2021	PBIO	Early Asu202006 Adoption EarlyAsu202006Adoption		usd
CY2021	PBIO	Conversion Of Preferred Stock For Common Stock ConversionOfPreferredStockForCommonStock		usd
CY2022	PBIO	Discount Due To Beneficial Conversion Feature DiscountDueToBeneficialConversionFeature		usd
CY2022	PBIO	Non Cash Deemed Dividendbeneficial Conversion Feature NonCashDeemedDividendbeneficialConversionFeature		usd
CY2022	PBIO	Conversion Of Debt For Preferred Stock ConversionOfDebtForPreferredStock		usd
CY2022	PBIO	Recognition Of Right Of Use Asset And Liability RecognitionOfRightOfUseAssetAndLiability		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive		usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38185
CY2022	dei	Entity Registrant Name EntityRegistrantName	PRESSURE BIOSCIENCES, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MA
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-2652826
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	14 Norfolk Avenue
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	South Easton
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02375
CY2022	dei	City Area Code CityAreaCode	508
CY2022	dei	Local Phone Number LocalPhoneNumber	230-1828
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	17966105	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15867711	shares
CY2022	dei	Auditor Firm AuditorFirmId	206
CY2022	dei	Auditor Name AuditorName	MaloneBailey, LLP
CY2022	dei	Auditor Location AuditorLocation	Houston, Texas
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3865	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132311	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	295374	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	154746	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	982973	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	342496	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	686383	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1147554	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	257527	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	422617	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1243149	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1857228	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	63638	usd
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	59976	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	103351	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	115846	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	282095	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	395565	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	317308	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	403846	usd
CY2022Q4	us-gaap	Assets Assets	2009541	usd
CY2021Q4	us-gaap	Assets Assets	2832461	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	637238	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	527924	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	167247	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	117680	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2497762	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1955672	usd
CY2022Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	10803983	usd
CY2021Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	7757217	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	58242	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	37124	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	17823669	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	12839813	usd
CY2022Q4	PBIO	Other Debt Unamortized Discounts Net OtherDebtUnamortizedDiscountsNet	0	usd
CY2021Q4	PBIO	Other Debt Unamortized Discounts Net OtherDebtUnamortizedDiscountsNet	0	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1638969	usd
CY2021Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1256840	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	634885	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	142171	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	132996	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34404166	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24625266	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	139924	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	262569	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1822	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3587	usd
CY2022Q4	us-gaap	Liabilities Liabilities	34695912	usd
CY2021Q4	us-gaap	Liabilities Liabilities	25041422	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1098	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	1099	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13682910	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13682910	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9120526	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9120526	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	136829	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	91206	usd
CY2022Q4	PBIO	Warrants To Acquire Common Stock WarrantsToAcquireCommonStock	31995762	usd
CY2021Q4	PBIO	Warrants To Acquire Common Stock WarrantsToAcquireCommonStock	31715154	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69006145	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	64261048	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133826205	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118277468	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-32686371	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-22208961	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2009541	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2832461	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1729343	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2002365	usd
CY2022	us-gaap	Revenues Revenues	1729343	usd
CY2021	us-gaap	Revenues Revenues	2002365	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2014004	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	942383	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	969532	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1101509	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	401444	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	324728	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3242652	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3818892	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	6627632	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	6187512	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4898289	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-4185147	usd
CY2022	us-gaap	Interest Expense InterestExpense	10438565	usd
CY2021	us-gaap	Interest Expense InterestExpense	14450241	usd
CY2022	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	3662	usd
CY2021	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-457025	usd
CY2022	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-751335	usd
CY2021	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-1061073	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7849	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11178389	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15968339	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16076678	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20153486	usd
CY2021	PBIO	Deemed Dividends On Beneficial Conversion Feature DeemedDividendsOnBeneficialConversionFeature	873798	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1727275	usd
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1658175	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17803953	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22685459	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.61
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.42
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11058356	shares
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-6738802	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	110128	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-16917592	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	254615	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14773	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	1320331	usd
CY2021	PBIO	Beneficial Conversion Option On Convertible Preferred Stock BeneficialConversionOptionOnConvertiblePreferredStock	873798	usd
CY2021	PBIO	Deemed Dividend On Convertible Preferred Stock DeemedDividendOnConvertiblePreferredStock	-873798	usd
CY2021	PBIO	Preferred Stock Issued For Debt Settlement PreferredStockIssuedForDebtSettlement	523254	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2989990	usd
CY2021	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	184274	usd
CY2021	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	6665656	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	794562	usd
CY2021	PBIO	Stock Issued With Debt StockIssuedWithDebt	646718	usd
CY2021	PBIO	Preferred Stock Offering PreferredStockOffering	1015000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	1658175	usd
CY2021	PBIO	Issuance Of Common Stock Warrants For Interest Paid In Kind IssuanceOfCommonStockWarrantsForInterestPaidInKind	600298	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1403546	usd
CY2021	PBIO	Warrants Issued With Debt Settlement WarrantsIssuedWithDebtSettlement	107275	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20153486	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-22208961	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-22208961	usd
CY2022	PBIO	Cumulative Effect Period Of Adoption Adjustment CumulativeEffectPeriodOfAdoptionAdjustment	-473027	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	215098	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17443	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	1727275	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	392175	usd
CY2022	PBIO	Warrants Issued For Debt Extension WarrantsIssuedForDebtExtension	132537	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2198861	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	467092	usd
CY2022	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	386300	usd
CY2022	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	2943139	usd
CY2022	PBIO	Stock Issued With Debt StockIssuedWithDebt	873854	usd
CY2022	PBIO	Sale Of Common Stock For Cash SaleOfCommonStockForCash	25000	usd
CY2022	PBIO	Warrants Issued For Services WarrantsIssuedForServices	54495	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	93576	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16076678	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-32686371	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16076678	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20153486	usd
CY2022	PBIO	Gain On Loan Forgiveness GainOnLoanForgiveness	10000	usd
CY2021	PBIO	Gain On Loan Forgiveness GainOnLoanForgiveness	734077	usd
CY2022	PBIO	Noncash Lease Expense Income NoncashLeaseExpenseIncome	113470	usd
CY2021	PBIO	Noncash Lease Expense Income NoncashLeaseExpenseIncome	65194	usd
CY2022	PBIO	Common Stock And Warrants Issued For Interest CommonStockAndWarrantsIssuedForInterest	2943139	usd
CY2021	PBIO	Common Stock And Warrants Issued For Interest CommonStockAndWarrantsIssuedForInterest	7265954	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	119788	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1777863	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2331398	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-130279	usd
CY2022	PBIO	Allowance For Inventory Reserve AllowanceForInventoryReserve	641815	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	215098	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	254615	usd
CY2022	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	3662	usd
CY2021	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	-457025	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	446670	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	794562	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	140628	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23518	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	180644	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	554787	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-165090	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	107681	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	109314	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-226771	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	49567	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	15106	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-113470	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-65194	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3133829	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1165276	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4478041	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4868573	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20755	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	122945	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20755	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-122945	usd
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	1015000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17443	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14773	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4907222	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5514250	usd
CY2022	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	2710000	usd
CY2021	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	2010688	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	866350	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	254600	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1522494	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1833295	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	315300	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	354600	usd
CY2022	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	2317871	usd
CY2021	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1516127	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4370350	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5105289	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-128446	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	113771	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	132311	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18540	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3865	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	132311	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1378647	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	921569	usd
CY2021	PBIO	Common Stock Issued For Noncash Warrant Exercise CommonStockIssuedForNoncashWarrantExercise	363	usd
CY2022	PBIO	Early Asu202006 Adoption EarlyAsu202006Adoption	473027	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	873854	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	646718	usd
CY2022	PBIO	Discount From Warrants Issued With Debt DiscountFromWarrantsIssuedWithDebt	93576	usd
CY2021	PBIO	Discount From Warrants Issued With Debt DiscountFromWarrantsIssuedWithDebt	1403546	usd
CY2022	PBIO	Common Stock Issued In Lieu Of Cash For Dividend CommonStockIssuedInLieuOfCashForDividend	386300	usd
CY2021	PBIO	Common Stock Issued In Lieu Of Cash For Dividend CommonStockIssuedInLieuOfCashForDividend	184274	usd
CY2022	PBIO	Noncash Preferred Stock Dividends NoncashPreferredStockDividends	1727275	usd
CY2021	PBIO	Noncash Preferred Stock Dividends NoncashPreferredStockDividends	1658175	usd
CY2022	PBIO	Conversion Of Preferred Stock For Common Stock ConversionOfPreferredStockForCommonStock	44	usd
CY2022	PBIO	Conversion Of Debt Into Common Stock ConversionOfDebtIntoCommonStock	467092	usd
CY2021	PBIO	Conversion Of Debt Into Common Stock ConversionOfDebtIntoCommonStock	2989990	usd
CY2021	PBIO	Discount Due To Beneficial Conversion Feature DiscountDueToBeneficialConversionFeature	1320331	usd
CY2021	PBIO	Non Cash Deemed Dividendbeneficial Conversion Feature NonCashDeemedDividendbeneficialConversionFeature	873798	usd
CY2021	PBIO	Conversion Of Debt For Preferred Stock ConversionOfDebtForPreferredStock	500250	usd
CY2021	PBIO	Recognition Of Right Of Use Asset And Liability RecognitionOfRightOfUseAssetAndLiability	239327	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zBmGZeQ9EKhf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ii. <span id="xdx_86D_zTMsIpmhwQb9">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2728243	usd
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2255216	usd
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	473027	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1729000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2002000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1729000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2002000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1729000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2002000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.61
CY2022Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	295000	usd
CY2021Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	155000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	60000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	41000	usd
CY2022Q4	PBIO	Extended Warranty Service ExtendedWarrantyService	60000	usd
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.42
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	188587	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	296892	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1480769	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1193158	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	982973	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	342496	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	686383	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1147554	usd
CY2022Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	317308	usd
CY2021Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	403846	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zMmA4FJ5Jzi3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>xii. <span id="xdx_864_zabQl5X9HvT3">Concentrations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Credit Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected. At December 31, 2022, we determined that no allowance against accounts receivable was necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--FairValueConcentrationOfRiskTextBlock_zwUaM3NKOxM5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zHOeuuQ9oCn" style="display: none">Schedule of Customer Concentration Risk Percentage</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Top Five Customers</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZpUjdwtbH4j" title="Concentration credit risk percentage">24</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20211231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziYJDEH889hd" title="Concentration credit risk percentage">44</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Federal Agencies</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zv6KgvoS3dWf" title="Concentration credit risk percentage">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20211231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9wYQS8EBPFk" title="Concentration credit risk percentage">6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Top Five Customers</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWXAzvrNTn1h" title="Concentration credit risk percentage">93</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20211231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1RTq7wGrD5b" title="Concentration credit risk percentage">82</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Federal Agencies</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zJKNMpuMGtyf" title="Concentration credit risk percentage">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20211231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQs5QaCrr2ed" title="Concentration credit risk percentage">5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> </table> <p id="xdx_8AC_zY6xmzMbHTG5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investment in Equity Securities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, we held <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20221231__dei--LegalEntityAxis__custom--NexityGlobalSAMember_zMWe8ST0LlE2" title="Sale of stock number of shares received">100,250</span> shares of common stock of Nexity Global SA, (a Polish publicly traded company). On October 23, 2020 Everest Investments S.A. changed its name to Nexity Global S.A. Nexity is and Everest was listed on the Warsaw Stock Exchange.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We had exchanged <span id="xdx_90B_ecustom--NumberOfCommonStockSharesExchangedDuringPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EverestMember_zv1CmASYoPx">33,334</span> shares of our common stock for the <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EverestMember_zPxiejSHvjdd">100,250</span> shares we had held in Everest (before the Nexity Merger). We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities.” ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs, of our investment in Nexity to be $<span id="xdx_907_eus-gaap--InvestmentOwnedAtFairValue_iI_c20221231__dei--LegalEntityAxis__custom--NexityGlobalSAMember_z5x99mC9fhni" title="Investment Owned, at Fair Value">63,638</span>. We recorded $<span id="xdx_909_eus-gaap--MarketableSecuritiesRealizedGainLoss_c20220101__20221231__dei--LegalEntityAxis__custom--NexityGlobalSAMember_z6zH2bPiZFV5" title="Unrealized gain">3,662</span> as unrealized gain during the year ended December 31, 2022 for changes in market value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">As of December 31, 2021, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs, of our investment in Nexity to be $<span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_iI_c20211231__dei--LegalEntityAxis__custom--NexityGlobalSAMember_z6fiJGG5kFQj" title="Investment Owned, at Fair Value">59,976</span>. We recorded $<span id="xdx_908_eus-gaap--MarketableSecuritiesRealizedGainLoss_c20210101__20211231__dei--LegalEntityAxis__custom--NexityGlobalSAMember_zdFkddwT7ga" title="Unrealized gain">457,025</span> as unrealized losses during the year ended December 31, 2021 for changes in market value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17803953	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22685459	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11058356	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6636523	shares
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	103351	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33647137	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31921119	shares
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	215098	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	254615	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	215098	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	254615	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	49135	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	15312	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y1M2D
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	140455	usd
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y1M2D
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	510878	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	487	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	17594	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	63638	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	59976	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	374132	usd
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	353379	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	194999	usd
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	194999	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	25248	usd
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	25248	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	53098	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	53098	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	647477	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	626724	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	544126	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	115846	usd
CY2022	us-gaap	Depreciation Depreciation	33250	usd
CY2021	us-gaap	Depreciation Depreciation	23589	usd
CY2022	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P9Y
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	80000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	80000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	80000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	80000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	80000	usd
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	750000	usd
CY2021Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	750000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	432692	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	346154	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	317308	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	403846	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	86538	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	86538	usd
CY2022	us-gaap	Pension Contributions PensionContributions	12777	usd
CY2021	us-gaap	Pension Contributions PensionContributions	11752	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	268548	usd
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	93570	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	99362	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	91792	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	15715	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	15169	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	872967	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	814202	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	104609	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	104609	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31026899	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	28435535	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	32388100	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29554877	usd
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	70711859	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	149300	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	64393	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	66969	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	51778	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	332440	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	50345	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	282095	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-113470	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-65194	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	282095	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	395565	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	142171	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	132996	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	139924	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	262569	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	282095	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	395565	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y11M15D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	0	usd
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	0	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	151239	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	87383	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	91800	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	91800	usd
CY2022	us-gaap	Lease Cost LeaseCost	243039	usd
CY2021	us-gaap	Lease Cost LeaseCost	179183	usd
CY2022Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	541313	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1522494	usd
CY2022	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	March, 2020 to December, 2023
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	12000000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	18279186	usd
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	14376462	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	455517	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1536649	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	17823669	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	12839813	usd
CY2022	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022	PBIO	Debt Default Convertible Conversion Ratio DebtDefaultConvertibleConversionRatio	0.75	pure
CY2022	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
CY2022	PBIO	Debt Default Convertible Conversion Ratio DebtDefaultConvertibleConversionRatio	0.75	pure
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022	us-gaap	Debt Instrument Convertible Conversion Price Decrease DebtInstrumentConvertibleConversionPriceDecrease	2.50
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	2.50
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022Q4	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	1	usd
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022Q4	PBIO	Percentage Of Price Rate PercentageOfPriceRate	0.10	pure
CY2022Q4	PBIO	Convertible Lesser Per Share ConvertibleLesserPerShare	2.5
CY2022Q4	PBIO	Convertible Lesser Discount Percent ConvertibleLesserDiscountPercent	0.25	pure
CY2022	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.35	pure
CY2022Q4	PBIO	Convertible Lesser Per Share ConvertibleLesserPerShare	2.50
CY2022Q4	PBIO	Convertible Lesser Discount Percent ConvertibleLesserDiscountPercent	0.25	pure
CY2022	us-gaap	Debt Instrument Convertible Threshold Trading Days DebtInstrumentConvertibleThresholdTradingDays	5	integer
CY2022Q4	PBIO	Default Convertible Lesser Price Per Share DefaultConvertibleLesserPricePerShare	2.50
CY2022Q4	PBIO	Debt Instrument Trading Percent DebtInstrumentTradingPercent	0.90	pure
CY2022	us-gaap	Debt Instrument Increase Decrease For Period Net DebtInstrumentIncreaseDecreaseForPeriodNet	1815000	usd
CY2022Q4	PBIO	Increased Debt Instrument Face Amount IncreasedDebtInstrumentFaceAmount	3024561	usd
CY2022Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	1788969	usd
CY2021Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	1406840	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1638969	usd
CY2021Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1256840	usd
CY2022	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-05-02
CY2022Q4	PBIO	Non Convertible Debt Instrument Amount NonConvertibleDebtInstrumentAmount	861500	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	150000	usd
CY2022Q4	PBIO	Accrued Interest Rate Percent AccruedInterestRatePercent	0.0375	pure
CY2022	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	731	usd
CY2022Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	1098	usd
CY2021Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	1099	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15790603	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	15302830	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2259408	shares
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	208911	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	275502	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	25389	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17540209	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	17308567	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	277500	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	25279	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	205839	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17586591	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	17570591	shares
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1307822	shares
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.72
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1291822	shares
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.69
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	25279	shares
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17443	usd
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	255500	shares
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	392175	usd
CY2022	PBIO	Stock Issued During Period Shares Issued For Debt Extensions StockIssuedDuringPeriodSharesIssuedForDebtExtensions	1423800	shares
CY2022	PBIO	Stock Issued During Period Value Issued For Debt Extensions StockIssuedDuringPeriodValueIssuedForDebtExtensions	2198861	usd
CY2022	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	181918	shares
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	467092	usd
CY2022	PBIO	Stock Issued During Period Shares Conversion Of Preferred Stock StockIssuedDuringPeriodSharesConversionOfPreferredStock	4400	shares
CY2022	PBIO	Stock Issued During Period Value Interest Paid In Kind StockIssuedDuringPeriodValueInterestPaidInKind	2943139	usd
CY2022	PBIO	Stock Issued During Period Shares Issued For Debt StockIssuedDuringPeriodSharesIssuedForDebt	659000	shares
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	873854	usd
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10000	shares
CY2021	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	333200	shares
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	794562	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	36290	shares
CY2021	PBIO	Stock Issued With Debt StockIssuedWithDebt	646718	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	2700000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	6288529	usd
CY2020Q4	us-gaap	Debt Instrument Description DebtInstrumentDescription	we are obligated to issue 100,000 warrants if the loan is not repaid before January 23, 2021 and an additional 10,000 shares of common stock and 100,000 warrants if the loan is not repaid before February 23, 2021. We are also obligated to issue 10,000 shares of common stock and 200,000 warrants if the loan is not repaid before March 23, 2021. During the year ended December 31, 2021 the Company issued 400,000 warrants to this lender ($3.50 exercise price and five-year term) with a fair value of $600,298. The Company is also obligated to issue 10,000 shares of common stock to this lender every 31 days up to the loan’s maturity date on June 23, 2021.
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	9393150	usd
CY2020Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1535500	usd
CY2020Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	9390000	usd

Files In Submission

Name	View Source	Status
0001493152-23-012010-index-headers.html	Edgar Link	pending
0001493152-23-012010-index.html	Edgar Link	pending
0001493152-23-012010.txt	Edgar Link	pending
0001493152-23-012010-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbio-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
pbio-20221231_cal.xml	Edgar Link	unprocessable
pbio-20221231_def.xml	Edgar Link	unprocessable
pbio-20221231_lab.xml	Edgar Link	unprocessable
pbio-20221231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio

2023 Q1 Form 10-K Financial Statement

#000149315223012010 Filed on April 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBIO PRESSURE BIOSCIENCES INC Stock $pbio

2023 Q1 Form 10-K Financial Statement

#000149315223012010 Filed on April 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio